

Oct. 31, 2018

340B Lobbying Surges in 2018

The number of groups lobbying federal offices on the 340B drug pricing program surged in 2018, reaching 203 organizations in the second quarter of 2018 and dipping to 186 in the third quarter. The Trump administration first proposed cuts to the program last year, in addition to the cuts that CMS proposed in July.

The 340B program requires pharmaceutical companies participating in Medicaid to sell outpatient drugs at a reduced cost to eligible health care providers that serve a disproportionate share of low-income and under-insured patients. The drug industry has argued that 340B has grown too large in recent years and that participating hospitals aren't doing a good job of sharing the savings with patients.

Number of unique clients lobbying federal offices on 340B drug pricing program

